Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.05 -0.16 (-0.63%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗

March 25, 2022

Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.

Via Investor's Business Daily

Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗

March 23, 2022

Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.

Via Investor's Business Daily

Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating ↗

March 08, 2022

Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82.

Via Investor's Business Daily

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Expert Ratings For Pacira BioSciences ↗

November 05, 2021

Within the last quarter, Pacira BioSciences (NASDAQ:PCRX) has observed the...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating ↗

February 07, 2022

The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.

Via Investor's Business Daily

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

PCRX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Earnings Scheduled For November 3, 2021 ↗

November 03, 2021

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher ↗

October 11, 2021

Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened...

Via Talk Markets

Topics Stocks

Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition ↗

October 11, 2021

Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value...

Via Benzinga

Why Pacira Biosciences Stock Sank Today ↗

October 04, 2021

A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug.

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 04, 2021

Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

Pacira BioSciences, inc (PCRX) Q2 2021 Earnings Call Transcript ↗

August 03, 2021

PCRX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Earnings Outlook For Pacira BioSciences ↗

August 02, 2021

Pacira BioSciences (NASDAQ:PCRX) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021 ↗

July 26, 2021

Upgrades Tudor Pickering upgraded the previous rating for Precision Drilling Corp (NYSE:

Via Benzinga

Earnings Scheduled For August 3, 2021 ↗

August 03, 2021

Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to...

Via Benzinga

Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries ↗

May 26, 2021

Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal...

Via Benzinga

Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important ↗

May 13, 2021

Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug. What Happened: San Diego,...

Via Benzinga

Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript ↗

May 04, 2021

PCRX earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2021

Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid...

Via Benzinga

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Earnings Scheduled For May 4, 2021 ↗

May 04, 2021

Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 27, 2021

Gainers BioVie (NASDAQ:BIVI) shares rose 11.62% to $24.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 27.3K shares,...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.